|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/05/24 Helius Medical Technologies, Inc. 8-K:3 4/04/24 10:169K Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 37K 5: R1 Document and Entity Information HTML 47K 7: XML IDEA XML File -- Filing Summary XML 12K 10: XML XBRL Instance -- hsdt-20240404x8k_htm XML 16K 6: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 3: EX-101.LAB XBRL Labels -- hsdt-20240404_lab XML 46K 4: EX-101.PRE XBRL Presentations -- hsdt-20240404_pre XML 31K 2: EX-101.SCH XBRL Schema -- hsdt-20240404 XSD 13K 8: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K 9: ZIP XBRL Zipped Folder -- 0001558370-24-004788-xbrl Zip 22K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i April 4, 2024
i HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
- | | |
i Delaware | i 36-4787690 | |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
i 642 Newtown Yardley Road, i Suite 100 |
| i 18940 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: i (215) i 944-6100
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
i Class A Common Stock, $0.001 par value | | i HSDT | | i The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On April 4, 2024, Helius Medical Technologies, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Stock Market LLC because the Company’s stockholders' equity, as reported in the Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2023, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards.
Under applicable Nasdaq rules, the Company has 45 calendar days from the date of the notice, or until May 20, 2024, to submit a plan to regain compliance. The Company intends to timely submit such a plan to Nasdaq. If the Company’s plan is accepted, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the notice to evidence compliance.
The notice has no immediate impact on the listing of the Company’s common stock, which will continue to trade on The Nasdaq Stock Market LLC under the symbol “HSDT”.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | HELIUS MEDICAL TECHNOLOGIES, INC. | |
| | | |
Dated: April 5, 2024 | | By: | |
| | | |
| | | Chief Financial Officer, Treasurer and Secretary |
2
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 5/20/24 | ||||
| Filed on: | 4/5/24 | |||
| For Period end: | 4/4/24 | |||
| 12/31/23 | 10-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/08/24 Helius Medical Technologies, Inc. 424B4 1:342K Toppan Merrill/FA 4/26/24 Helius Medical Technologies, Inc. S-1/A 9:1.1M Toppan Merrill/FA 4/15/24 Helius Medical Technologies, Inc. S-1 3:520K Toppan Merrill/FA |